To help address any concerns about undue influence on prescriber behaviour and to introduce more transparency into our marketing and educational efforts, we’re stopping payments to healthcare professionals to speak on GSK’s behalf about our prescription medicines and vaccines.
Transfer of value reports
As a member of Medicines Australia, GlaxoSmithKline Australia has undertaken to be open and transparent when we provide a reportable payment or transfer of value to a healthcare professional. Reportable payments or transfers of value include:
- Payments for the provision of services such as giving a lecture, chairing an educational meeting, providing advice as a member of an Advisory Board or as a Consultant
- Airfares, accommodation and/or conference registration fees to attend medical education as part of those services.
GlaxoSmithKline Australia has prepared the report for publication in accordance with the Medicines Australia Code of Conduct, Edition 18 and Australia’s Privacy legislation. The report identifies healthcare professionals by name where their consent has been provided. Where consent has not been provided the information is reported in aggregate.
From 1 October 2016, reporting these payments will be mandatory – details will be reported because healthcare professionals should reasonably expect that all reportable payments or transfers of value will be disclosed for each healthcare professional, by name.
In 2013, GSK announced that it would stop paying healthcare professionals to speak on its behalf about our prescription medicines and vaccines. This new approach came into effect on 1 January 2016.
To comply with our privacy obligations, the report may be amended from time to time. The report here contains the most up to date information. Any use or disclosure of the data by a third party is the responsibility of that third party, who must comply with the Australian Privacy Act 1988.
For further information about the details in the report, please go to medicinesaustralia.com.au